Brought to you by 
Complix to develop cancer Alphabodies for MSD
28 Jul 2017
Executive Summary
Complix NV agreed to use its Alphabody protein therapeutic discovery platform to develop Cell-Penetrating Alphabodies (CPABs) against up to two intracellular cancer targets for Merck Sharp & Dohme Ltd. (MSD).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Complix to develop cancer Alphabodies for MSD
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice